• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

长期使用C1抑制剂(C1 INH)浓缩物对遗传性和获得性C1抑制剂缺乏所致复发性血管性水肿患者进行预防治疗。

Long-term prophylaxis with C1-inhibitor (C1 INH) concentrate in patients with recurrent angioedema caused by hereditary and acquired C1-inhibitor deficiency.

作者信息

Bork K, Witzke G

机构信息

Department of Dermatology, Johannes Gutenberg University, Mainz, Federal Republic of Germany.

出版信息

J Allergy Clin Immunol. 1989 Mar;83(3):677-82. doi: 10.1016/0091-6749(89)90082-1.

DOI:10.1016/0091-6749(89)90082-1
PMID:2926086
Abstract

A case of hereditary angioedema (HAE) type I (inherited C1-inhibitor [C1 INH] deficiency) and a case of late-onset acquired C1 INH with angioedema is described. In both patients, long-term prophylaxis with C1 INH had become necessary because treatment with danazol and epsilon-aminocaproic acid was not effective or not tolerated. Consequently, both patients received a pasteurized concentrate of C1 INH continuously for a period of 1 year in a dosage that kept them free of symptoms. The patient with HAE was administered 500 units of C1 INH intravenously every 4 or 5 days, whereas the patient with acquired angioedema required 1000 units of C1 INH every 5 days. As a result of this long-term prophylaxis, both patients became free or nearly free from their episodes of cutaneous and internal edema. The low plasma levels of C1 INH, C4, and C2, rose. In the patient with acquired C1 INH deficiency, the swellings increasingly reappeared after 10 months, although the patient's antibody titer did not rise during treatment. No side effects were recorded during therapy. In particular, both patients remained HIV and hepatitis B antibody negative.

摘要

本文描述了1例I型遗传性血管性水肿(HAE,遗传性C1抑制物[C1 INH]缺乏症)和1例迟发性获得性C1 INH缺乏伴血管性水肿的病例。在这2例患者中,由于使用达那唑和ε-氨基己酸治疗无效或无法耐受,因此有必要长期使用C1 INH进行预防。因此,2例患者均连续1年接受经巴氏消毒的C1 INH浓缩物治疗,剂量足以使其无症状。HAE患者每4或5天静脉注射500单位C1 INH,而获得性血管性水肿患者每5天需要1000单位C1 INH。经过这种长期预防,2例患者的皮肤和内脏水肿发作均消失或几乎消失。C1 INH、C4和C2的低血浆水平有所上升。在获得性C1 INH缺乏症患者中,尽管治疗期间患者的抗体滴度未升高,但10个月后肿胀越来越多地再次出现。治疗期间未记录到副作用。特别是,2例患者的HIV和乙肝抗体均保持阴性。

相似文献

1
Long-term prophylaxis with C1-inhibitor (C1 INH) concentrate in patients with recurrent angioedema caused by hereditary and acquired C1-inhibitor deficiency.长期使用C1抑制剂(C1 INH)浓缩物对遗传性和获得性C1抑制剂缺乏所致复发性血管性水肿患者进行预防治疗。
J Allergy Clin Immunol. 1989 Mar;83(3):677-82. doi: 10.1016/0091-6749(89)90082-1.
2
Hereditary angioedema: a decade of human C1-inhibitor concentrate therapy.遗传性血管性水肿:人类C1抑制物浓缩剂治疗的十年
J Allergy Clin Immunol. 2007 Oct;120(4):941-7. doi: 10.1016/j.jaci.2007.06.026. Epub 2007 Aug 29.
3
[Therapeutic approach of hereditary angioedema].[遗传性血管性水肿的治疗方法]
Rev Assoc Med Bras (1992). 2004 Jul-Sep;50(3):314-9. doi: 10.1590/s0104-42302004000300041. Epub 2004 Oct 21.
4
[Hereditary angioedema in the German-speaking region].[德语区的遗传性血管性水肿]
Hautarzt. 1998 Feb;49(2):114-22. doi: 10.1007/s001050050710.
5
Treatment of 193 episodes of laryngeal edema with C1 inhibitor concentrate in patients with hereditary angioedema.遗传性血管性水肿患者应用C1抑制剂浓缩物治疗193例喉水肿发作。
Arch Intern Med. 2001 Mar 12;161(5):714-8. doi: 10.1001/archinte.161.5.714.
6
Hereditary and acquired C1-inhibitor deficiency: biological and clinical characteristics in 235 patients.遗传性和获得性C1抑制剂缺乏症:235例患者的生物学和临床特征
Medicine (Baltimore). 1992 Jul;71(4):206-15. doi: 10.1097/00005792-199207000-00003.
7
Clinical problems in the C1-inhibitor deficient patient.C1抑制剂缺乏患者的临床问题。
Behring Inst Mitt. 1993 Dec(93):306-12.
8
[The use of a C1-inhibior concentrate for short-term preoperative prophylaxis in two patients with hereditary angioedema].[C1抑制剂浓缩物用于两名遗传性血管性水肿患者术前短期预防]
Anaesthesist. 1996 Jul;45(7):626-30. doi: 10.1007/s001010050295.
9
C1-inhibitor deficiency and angioedema.C1抑制物缺乏与血管性水肿
Mol Immunol. 2001 Aug;38(2-3):161-73. doi: 10.1016/s0161-5890(01)00040-2.
10
The use of plasma-derived C1 inhibitor in the treatment of hereditary angioedema.使用血浆源性C1抑制剂治疗遗传性血管性水肿。
Expert Opin Pharmacother. 2007 Dec;8(18):3173-81. doi: 10.1517/14656566.8.18.3173.

引用本文的文献

1
The Benefits of Complement Measurements for the Clinical Practice.补体测量在临床实践中的益处。
Methods Mol Biol. 2021;2227:1-20. doi: 10.1007/978-1-0716-1016-9_1.
2
Current and Prospective Targets of Pharmacologic Treatment of Hereditary Angioedema Types 1 and 2.遗传性血管性水肿 1 型和 2 型的药物治疗的当前和潜在靶点。
Clin Rev Allergy Immunol. 2021 Aug;61(1):66-76. doi: 10.1007/s12016-021-08832-x. Epub 2021 Jan 9.
3
Acquired and hereditary forms of recurrent angioedema: Update of treatment.获得性和遗传性复发性血管性水肿:治疗进展
Allergol Select. 2018 Sep 1;2(1):121-131. doi: 10.5414/ALX1561E. eCollection 2018.
4
[Angioedema prophylaxis].[血管性水肿预防]
Hautarzt. 2019 Feb;70(2):107-115. doi: 10.1007/s00105-018-4345-9.
5
Optimum Use of Acute Treatments for Hereditary Angioedema: Evidence-Based Expert Consensus.遗传性血管性水肿急性治疗的最佳应用:基于证据的专家共识。
Front Med (Lausanne). 2018 Mar 12;4:245. doi: 10.3389/fmed.2017.00245. eCollection 2017.
6
Efficacy and safety of an intravenous C1-inhibitor concentrate for long-term prophylaxis in hereditary angioedema.静脉注射C1抑制剂浓缩物用于遗传性血管性水肿长期预防的疗效和安全性。
Allergy Rhinol (Providence). 2017 Mar 1;8(1):13-19. doi: 10.2500/ar.2017.8.0192.
7
The Humanistic, Societal, and Pharmaco-economic Burden of Angioedema.血管性水肿的人文、社会及药物经济学负担
Clin Rev Allergy Immunol. 2016 Oct;51(2):230-9. doi: 10.1007/s12016-016-8575-2.
8
A Decade of Change: Recent Developments in Pharmacotherapy of Hereditary Angioedema (HAE).十年之变:遗传性血管性水肿(HAE)药物治疗的最新进展
Clin Rev Allergy Immunol. 2016 Oct;51(2):183-92. doi: 10.1007/s12016-016-8544-9.
9
Complement, a target for therapy in inflammatory and degenerative diseases.补体,炎症和退行性疾病的治疗靶点。
Nat Rev Drug Discov. 2015 Dec;14(12):857-77. doi: 10.1038/nrd4657. Epub 2015 Oct 23.
10
Pharmacokinetics of plasma-derived C1-esterase inhibitor after subcutaneous versus intravenous administration in subjects with mild or moderate hereditary angioedema: the PASSION study.在患有轻度或中度遗传性血管性水肿的受试者中,皮下注射与静脉注射血浆衍生的 C1 酯酶抑制剂后的药代动力学:PASSION 研究。
Transfusion. 2014 Jun;54(6):1552-61. doi: 10.1111/trf.12501. Epub 2013 Nov 24.